Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sernova Biotherapeutics Inc. (SEOVF : OTC)
 
 • Company Description   
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. Sernova Biotherapeutics, formerly known as Sernova Corp., is based in LONDON, Ontario.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.12 Daily Weekly Monthly
20 Day Moving Average: 11,542 shares
Shares Outstanding: 328.48 (millions)
Market Capitalization: $38.70 (millions)
Beta: 1.00
52 Week High: $0.25
52 Week Low: $0.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.59% -5.27%
12 Week -17.16% -30.32%
Year To Date -21.47% -26.45%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
700 COLLIP CIRCLE SUITE 114
-
LONDON,A6 N6G 4X8
CAN
ph: 519-858-5184
fax: 519-858-5099
david.burke@sernova.com http://www.sernova.com
 
 • General Corporate Information   
Officers
Jonathan Rigby - Chairman; President and Chief Executive Officer
James Parsons - Chief Financial Officer
Bernd Muehlenweg - Director
David Paterson - Director
Steven Sangha - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81752F106
SIC: 2834
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: 04/01/25
Next Expected EPS Date: 09/15/25
Share - Related Items
Shares Outstanding: 328.48
Most Recent Split Date: (:1)
Beta: 1.00
Market Capitalization: $38.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/15/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/25 - -
01/31/25 - -
10/31/24 - -
ROA
04/30/25 - -396.49
01/31/25 - -374.21
10/31/24 - -283.67
Current Ratio
04/30/25 - 0.12
01/31/25 - 0.10
10/31/24 - 0.32
Quick Ratio
04/30/25 - 0.12
01/31/25 - 0.10
10/31/24 - 0.32
Operating Margin
04/30/25 - -
01/31/25 - -
10/31/24 - -
Net Margin
04/30/25 - -
01/31/25 - -
10/31/24 - -
Pre-Tax Margin
04/30/25 - -
01/31/25 - -
10/31/24 - -
Book Value
04/30/25 - -0.04
01/31/25 - -0.04
10/31/24 - -0.03
Inventory Turnover
04/30/25 - -
01/31/25 - -
10/31/24 - -
Debt-to-Equity
04/30/25 - -
01/31/25 - -
10/31/24 - -
Debt-to-Capital
04/30/25 - -
01/31/25 - -
10/31/24 - -
 

Powered by Zacks Investment Research ©